SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults

Matthew E. Levy, Evanette Burrows, Vanessa Chilunda, Pamala A. Pawloski, Phillip Heaton, Joseph J. Grzymski, Jason D. Goldman, Lisa M. McEwen, Dana Wyman, Andrew Dei Rossi, Hang Dai, Magnus Isaksson, Nicole Washington, Tracy Basler, Kevin Tsan, Jason Nguyen, Jimmy M. Ramirez, Efren Sandoval, William Lee, James T. Lu, Shishi LuoClinical 2024 · DOI

Abstract

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
BibTeX
@inproceedings{levy2024sars,
  author = {Matthew E. Levy and Evanette Burrows and Vanessa Chilunda and Pamala A. Pawloski and Phillip Heaton and Joseph J. Grzymski and Jason D. Goldman and Lisa M. McEwen and Dana Wyman and Andrew Dei Rossi and Hang Dai and Magnus Isaksson and Nicole Washington and Tracy Basler and Kevin Tsan and Jason Nguyen and Jimmy M. Ramirez and Efren Sandoval and William Lee and James T. Lu and Shishi Luo},
  title = {{SARS-CoV-2 Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1093/cid/ciad796},
}

Loading related content...

Figure